Prostate Cancer

Phase 1 trial of JANX014, a PSMA-targeted T-cell engager, begins in mCRPC, building on prior safety data to expand treatment strategies.

The first patient has been dosed in a phase 1 trial (NCT05997615) of VIR-5500, a dual-masked PSMA-targeting T-cell engager for metastatic prostate cancer.

Transdermal estradiol offers fewer hot flashes and lower fracture rates, but higher rates of gynecomastia, as it meets the noninferiority bar against LHRH agonists.

Early results from TALAPRO-3 suggest that the combination of talazoparib and enzalutamide may redefine the treatment paradigm for HRR gene-mutated mCSPC, demonstrating that targeting DNA damage repair earlier in the disease course substantially delays radiographic progression.

A phase 3 trial evaluating TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) showed positive safety and toxicity profile in prostate cancer.

The FDA approves a new formulation of piflufolastat F 18, enhancing prostate cancer imaging with improved efficiency and patient access.

CAPItello-281 shows capivasertib plus abiraterone extends rPFS in PTEN-deficient mHSPC with manageable toxicity and preserved overall quality of life.

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

Findings from the phase 1 PAnTHA study demonstrate that actinium-225 was well tolerated with encouraging responses in patients with metastatic castration-resistant prostate cancer.

PEACE-3 data show enzalutamide plus radium-223 extends survival and delays progression in bone-predominant mCRPC, with manageable added toxicity.

The phase 2 BRCAAway trial demonstrated that abiraterone acetate, prednisone, and olaparib significantly improves progression-free survival and overall survival compared with either agent used alone or sequentially in patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 or ATM alterations.

Final overall survival data for PEACE-3 (NCT02194842) evaluating the combination of enzalutamide (Xtandi) and radium-223 (Xofigo) will be presented at the 2026 ASCO GU Cancers Symposium.

Actinium-225 is a targeted and highly-potent alpha emitter that holds promise for patients who do not respond to lutetium-177 therapy.

Bone-protecting therapies are an important part of delivering optimal care in patients with prostate cancer who are treated with androgen-deprivation therapy.

The 5-mg dose of oxybutynin reduced the frequency and severity of hot flashes in men with prostate cancer undergoing treatment with androgen-deprivation therapy compared with placebo.

New ASCO Living Guidelines on prostate cancer emphasize first-line therapies, bone protection, and the growing role of genetic testing.

Rucaparib receives full FDA approval for treating metastatic castration-resistant prostate cancer, offering a vital chemotherapy-free option for patients.

FDA approves a new treatment combining niraparib and abiraterone for BRCA2-mutated metastatic prostate cancer, enhancing patient outcomes.

JANX007 shows promising efficacy and manageable safety in treating metastatic castration-resistant prostate cancer, with significant PSA reductions and durable responses.

Che-Kai Tsao, MD, MS, discusses new approaches that could change the standard of care for metastatic hormone-sensitive prostate cancer.

The IsoPSA test revolutionizes prostate cancer diagnosis, enhancing risk assessment and reducing unnecessary biopsies for men with elevated PSA levels.

Recent polling shows oncologists' changing inclination in treatment for metastatic hormone-sensitive prostate cancer (mHSPC) based on tolerability profiles.